Estimated launch time of Inavolisib in the country

Inavolisib (Inavolisib), as a PI3Kα selective inhibitor that has attracted much attention in international oncology drug research in recent years, is regarded as a potentially important innovative drug in the global treatment of breast cancer. According to public information, the original research version Inavolisib was approved in China in March 2025, with the trade name "Ihelai". This time point means that China is highly synchronized with the international research and development pace, which further reflects the increasing domestic policy emphasis on innovative cancer drugs for precision therapy.

Judging from the speed of review, Chinese regulatory authorities have continued to accelerate the introduction of innovative drugs in the field of targeted tumor therapy in recent years, especially among breast cancer populations with clear genetic mutations and high unmet clinical needs. The PI3K pathway has always been a key focus. Inalise's clinical studies have been widely discussed internationally, and its design emphasizes highly selective inhibition of PI3Kα isoforms to reduce common toxicity issues with traditional PI3K inhibitors, thus showing potential value in the treatment of HER2-positive breast cancer with PIK3CA mutations.

The launch time of inaliside in China is driven by many factors, including a large domestic patient base, strong demand for mutation target drugs, and the gradual improvement of international multi-center research data. As more real-world evidence and overseas research results are released, China's formulation of its indications, usage scenarios and treatment specifications will also accelerate. It is expected that after the drug is launched, it will provide new precision treatment options for breast cancer patients with PIK3CA mutations, and may play a greater role in combination treatment strategies.

In the future, against the background of the gradual update of the domestic guideline system, the use of inalise may be expanded to more treatment stages, especially for patients with poor tolerance to previous treatments or insufficient response to traditional regimens. At the same time, as the commercialization process advances, its medical insurance inclusion and localization strategies will also become important issues of concern to the industry.

Reference materials:https://www.itovebi-hcp.com/